Regulation of MMP-9 gene expression for the development of novel molecular targets against cancer and inflammatory diseases

Bibliography

• COUSSENS LM, WERB Z: Inflammation and cancer. Nature (2002) 420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• ••An excellent review that re-examinesthe role of inflammation in tumour progression in the context of the peritumoral microenvironment, including a discussion on the importance of MMP expression and inflammatory mediators that control their expression.
   Google Scholar
• KANTARJIAN H, SAWYERS C, HOCHHAUS A et al.: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl. J. Med. (2002) 346(9):645–652.
   PubMed Web of Science ®Google Scholar
• EBERHARDT W, HUWILER A, BECK KF et al.: Amplification of IL-1P-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-icB and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. Immunol (2000) 165(10):5788–5797.
   Google Scholar
• SATO H, SEIKI M: Regulatory mechanism of 92 kDa Type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene (1993) 8(2):395–405.
   PubMed Web of Science ®Google Scholar
• SANCEAU J, BOYD DD, SEIKI M et al: Interferons inhibit tumor necrosis factor-a-mediated matrix metalloproteinase-9 activation via interferon regulatory factor-1 binding competition with NE-lc B. j Biol. Chem. (2002) 277(38):35766–35775.
   PubMedGoogle Scholar
• GUM R, LENGYEL E, JUAREZ J et al: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. Biol. Chem. (1996) 271(18):10672–10680.
   Google Scholar
• WATABE T, YOSHIDA K, SHINDOH M et al.: The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer (1998) 77(1):128–137.
   PubMedGoogle Scholar
• KOBAYASHI T, KISHIMOTO J, GE Yet al.: A novel mechanism of matrix metalloproteinase-9 gene expression implies a role for keratinization. EMBO Rep. (2001) 2(7):604–608.
   Google Scholar
• SHIMAJIRI S, ARIMA N, TANIMOTO A et al.: Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. (1999) 455(1-2):70–74.
   PubMed Web of Science ®Google Scholar
• HUANG TS, LEE CC, CHANG AC et al: Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. Biochem. Biophys. Res. Commun. (2003) 300(4):901–907.
   PubMedGoogle Scholar
• •A rare instance where a drug, in this case a compound which targets DNA Topoisomerase II, is capable of inhibiting MMP-9 expression by directly modifying the promoter, more specifically by shortening the d(CA) repeat.
   Google Scholar
• TREMBLAY P, HOUDE M, ARBOUR N et al.: Differential effects of PKC inhibitors on gelatinase B and interleukin 6 production in the mouse macrophage. Cytoki ne (1995) 7(2):130–136.
   PubMedGoogle Scholar
• JAKEN S: Protein kinase C isozymes and substrates. Curr. Opin. Cell. Biol. (1996) 8(2):168–173.
   PubMedGoogle Scholar
• ST-DENTS A, CHANO F, TREMBLAY P et al.: Protein kinase C-a modulates lipopolysaccharide-induced functions in a murine macrophage cell line. J. Biol. Chem. (1998) 273(49):32787–32792.
   PubMedGoogle Scholar
• XIE B, LAOUAR A, HUBERMAN E: Fibronectin-mediated cell adhesion is required for induction of 92-kDa Type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-I3. I. Biol. Chem. (1998) 273(19):11576–11582.
   Google Scholar
• RAO JS, STECK PA, MOHANAM S et al.: Elevated levels of M(r) 92,000 Type IV collagenase in human brain tumors. Cancer Res. (1993) 53(10 Suppl.):2208–2211.
   Google Scholar
• YAMAMOTO M, MOHANAM S, SAWAYA R et al.: Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and M vitro. Cancer R. (1996) 56(2):384–392.
   PubMedGoogle Scholar
• RAO JS, YAMAMOTO M, MOHAMAN S et al: Expression and localization of 92 kDa Type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin. Exp. Metastasis (1996) 14(1):12–18.
   PubMedGoogle Scholar
• FORSYTH PA, LAING TD, GIBSON AW et al.: High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. Neurooncol (1998) 36(1):21–29.
   PubMedGoogle Scholar
• KONDRAGANTI S, MOHANAM S, CHINTALA SK et al.: Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. (2000) 60(24) :6851–6855.
   PubMedGoogle Scholar
• ESTEVE PO, CHICOINE E, ROBLEDO O et al: Protein kinaseregulates transcriptionof the matrix metalloproteinase-9 gene induced by IL-1 and TNF-a in glioma cells via NF-icB. J. Biol. Chem. (2002) 277(38):35150–35155.
   PubMedGoogle Scholar
• •This study shows that targeting the PKC-mediated signalling cascade, implicating a specific isoform, can be efficient in inhibiting IVINIP-9 expression in cancer cells.
   Google Scholar
• PARK MJ, PARK IC, LEE HC et al: Protein kinase C-a activation by phorbol ester induces secretion of gelatinase B/MMP-9 through ERK 1/2 pathway in capillary endothelial cells. Int. J. Oncol (2003) 22(1):137–143.
   PubMedGoogle Scholar
• LI YT, SHEN F, LIU BH et al: Resveratrol inhibits matrix metalloproteinase-9 transcription in U937 cells. Acta Pharmacol SM. (2003) 24(11):1167–1171.
   Google Scholar
• WOO JH, LIM JH, KIM YH et al.: Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC-signal transduction. Oncogene (2004) 23(10):1845–1853.
   PubMedGoogle Scholar
• DIAZ-MECO MT, DOMINGUEZ I, SANZ L et al: PKC- induces phosphorylation and inactivation of IicB-a M vitro. EMBO J. (1994) 13(12):2842–2848.
   PubMedGoogle Scholar
• DIAZ-MECO MT, LOZANO J, MUNICIO MM et al: Evidence for the M vitro and in vivo interaction of Ras with protein kinase C J. Biol. Chem. (1994) 269(50):31706–31710.
   Google Scholar
• NOLAN GP, GHOSH S, LIOU HC et al: DNA binding and IicB inhibition of the cloned p65 subunit of NF-icB, a rel-related polypeptide. Cell (1991) 64(5):96i-969.
   Google Scholar
• RUBEN SM, DILLON PJ, SCHRECK R et al.: Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-icB. Science (1991) 254(5028):11.
   PubMedGoogle Scholar
• WILHELMSEN KC, EGGLETON K, TEMIN HM: Nucleic acid sequences of the oncogene v-rel in reticuloendotheliosis virus strain T and its cellular homolog, the proto-oncogeneVirol. (1984)52(1):172–182.
   Google Scholar
• RYSECK RP, BULL P, TAKAMIYA M et al.: RelB, a new Rel family transcription activator that can interact with p50-NF-icB. Ma Cell. Biol. (1992) 12:674–684.
   Google Scholar
• GHOSH S, GIFFORD AM, RIVIERE LR et al.: Cloning of the p50 DNA binding subunit of NF-icB: homology to rel and dorsal. Cell (1990) 62(5):1019–1029.
   PubMed Web of Science ®Google Scholar
• KIERAN M, BLANK V, LOGEAT F et al: The DNA binding subunit of NF-icB is identical to factor KBF1 and homologous to the rel oncogene product. Cell (1990) 62(5):1007–1018.
   PubMed Web of Science ®Google Scholar
• BOURS V, BURD PR, BROWN K et al: A novel mitogen-inducible gene product related to p50/p105-NF-icB participates in transactivation through a KB site. Ma Cell. Biol. (1992) 12(2):685–695.
   Google Scholar
• SCHMID PM, PERKINS ND, DUCKETT CS et al.: Cloning of an NF-icB subunit which stimulates HIV transcription in synergy with p65. Nature (1991) 352(6337):733–736.
   PubMedGoogle Scholar
• BALDWIN AS Jr: The NF-IcB and IicB proteins: new discoveries and insights. Annu. Rev Immunol (1996) 14:649–683.
   PubMed Web of Science ®Google Scholar
• WHITESIDE ST, ISRAEL A: IicB proteins: structure, function and regulation. Semin. Cancer Biol. (1997) 8(2):75–82.
   PubMedGoogle Scholar
• BROWN K, GERSTBERGER S, CARLSON L et al: Control of IicB-a proteolysis by site-specific, signal-induced phosphorylation. Science (1995) 267(5203):1485–1488.
   PubMed Web of Science ®Google Scholar
• CHEN ZJ, PARENT L, MANIATIS T: Site-specific phosphorylation of IxBa by a novel ubiquitination-dependent protein kinase activity. Cell (1996) 84(6):853–862.
   PubMed Web of Science ®Google Scholar
• TRAENCKNER EB, PAHL HL, HENKEL T et al: Phosphorylation of human IicB-a on serines 32 and 36 controls proteolysis and NF-icB activation in response to diverse stimuli. EMBOI. (1995) 14(12):2876–2883.
   PubMed Web of Science ®Google Scholar
• BREMNER P, HEINRICH M: Natural products as targeted modulators of the nuclear factor-KB pathway.]: Pharm. Phannacol (2002) 54(4):453–472.
   Google Scholar
• PISHA E, CHAI H, LEE IS et al: Discovery of betulinic acid as a selective inhibitor of human melanoma that functions by induction of apoptosis. Nat. Med. (1995) 1(10):1046–1051.
   PubMed Web of Science ®Google Scholar
• TAKADA Y, AGGARWAL BB: Betufinic acid suppresses carcinogen-induced NF-icB activation through inhibition of IicB a kinase and p65 phosphorylation: abrogation of cyclooxygenase-2 and matrix metalloprotease-9. Immunol. (2003) 171(03278–3286.
   Web of Science ®Google Scholar
• SHISHODIA S, MAJUMDAR S, BANERJEE S et al.: Ursofic acid inhibits nuclear factor-KB activation induced by carcinogenic agents through suppression of IxBa kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin Dl. Cancer Res. (2003) 63(15):4375–4383.
   PubMed Web of Science ®Google Scholar
• SHISHODIA S, POTDAR P, GAIROLA CG et al: Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-icB activation through inhibition of IxBa kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin Dl. Carcinogenesis (2003) 24(7):1269–1279.
   PubMed Web of Science ®Google Scholar
• •Curcurnin can be administered to humans safely and has received attention recently as a potent drug in lung diseases, including cystic fibrosis. This paper describes a molecular mechanism used by this natural compound to inhibit IVIIVIP-9 in pulmonary cells.
   Google Scholar
• YAN C, WANG H, BOYD DD: KiSS-1 represses 92-kDa Type IV collagenase expression by down-regulating NF-icB binding to the promoter as a consequence of IxBa -induced block of p65/p50 nuclear translocation. J. Biol. Chem. (2001) 276(2):1164–1172.
   PubMed Web of Science ®Google Scholar
• WOO JH, PARK JW, LEE SH et al.: Dykellic acid inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting nuclear factor-KB transcriptional activity. Cancer Res. (2003) 63(12):3430–3434.
   PubMedGoogle Scholar
• ASHIKAWA K, MAJUMDAR S, BANERJEE S et al.: Piceatannol inhibits TNF-induced NF-icB activation and NF-KB-mediated gene expression through suppression of IxBa kinase and p65 phosphorylation. Immunol (2002) 169(11):6490–6497.
   Google Scholar
• MOON SK, CHO GO, JUNG SY et al: Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. (2003) 301(4):1069–1078.
   PubMedGoogle Scholar
• •The french paradox lies in the DNA recognition motifs of the MMP-9 promoter. Another reason to keep good bottles of red Bordeaux at home.
   Google Scholar
• FORMICA JV, REGELSON W: Review of the biology of Quercetin and related bioflavonoids. Food Chem. Toxicol (1995) 33(12):1061–1080.
   PubMed Web of Science ®Google Scholar
• GALIS ZS, JOHNSON C, GODIN D et al.: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. (2002) 91(9):852–859.
   PubMed Web of Science ®Google Scholar
• COBB MH, GOLDSMITH EJ: How MAP kinases are regulated. J. Biol. Chem. (1995) 270(25):14843–14846.
   PubMed Web of Science ®Google Scholar
• KYRIAKIS JM, AVRUCH J: Sounding the alarm: protein kinase cascades activated by stress and inflammation. J. Biol. Chem. (1996) 271(40):24313–24316.
   PubMed Web of Science ®Google Scholar
• GARRINGTON TP, JOHNSON GL: Organization and regulation of mitogen-activated protein kinase signaling pathways. Carr: Opin. Cell Biol. (1999) 11:211–218.
   PubMed Web of Science ®Google Scholar
• LEWIS TS, SHAPIRO PS, AHN NG: Signal transduction through MAP kinase cascades. Adv. Cancer Res. (1998) 74:49–139.
   PubMed Web of Science ®Google Scholar
• MISSED, ESTEVE PO, RENNEBOOG B et al: HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38-mitogen-activated protein kinase signaling pathway. Blood (2001) 98(3):541–547.
   PubMedGoogle Scholar
• MOON SK, CHA BY, KIM CH: ERK1/2 mediates TNF-a-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-icB and AP-1: involvement of the ras dependent pathway. J. Cell Physiol (2004) 198(3):417–427.
   PubMedGoogle Scholar
• EBERHARDT W, SCHULZE M, ENGELS C et al: Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-KB and Ets transcription factors. MM. Endoccinol (2002) 16(8):1752–1766. 484 Expert Op/n. Ther. Targets (2004) 8(5)
   Google Scholar
• HOLVOET S, VINCENT C, SCHMITT D et al.: The inhibition of MAPK pathway is correlated with down-regulation of MMP-9 secretion induced by TNF-a in human keratinocytes. Exp. Cell Res. (2003) 290(1):108–119.
   PubMedGoogle Scholar
• VAYALIL PK, MITTAL A, KATIYAR SK: Proanthocyanidins from grape seeds inhibit expression of matrix metalloproteinases in human prostate carcinoma cells which is associated with the inhibition of activation of MAPK and NF-icB. Carcinogenesis (2004) 25(6):987–995.
   PubMedGoogle Scholar
• LAI WC, ZHOU M, SHANKAVARAM U et al.: Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (VIMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. Immunol. (2003) 170(12):6244–6249.
   Google Scholar
• LEE KH, HYUN MS, KIM JR: Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38-MAP kinase interaction in uPA synthesis. Clin. Exp. Metastasis (2003) 20(6):499–505.
   PubMedGoogle Scholar
• CORCORAN ML, STETLER-STEVENSON WG, BROWN PD et al.: Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa Type IV collagenase/gelatinase production by human monocytes. J. Biol. Chem. (1992) 267(1):515–519.
   PubMedGoogle Scholar
• CORCORAN ML, KIBBEY MC, KLEINMAN HK et al.: Laminin SIKVAV peptide induction of monocyte/macrophage prostaglandin E2 and matrix metalloproteinases. J. Biol. Chem. (1995) 270(18):10365–10368.
   PubMedGoogle Scholar
• ISHIWA J, SATO T, MIMAKI Y et al.: A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. Rheumatol (2000) 27(1):20–25.
   Google Scholar
• HAYES ME, DENTON J, FREEMONT AJ et al.: Synthesis of the active metabolite of vitamin D, 1, 25 (OH)2D3, by synovial fluid macrophages in arthritic diseases. Ann. Rheum. Dis. (1989) 48:723–729.
   PubMed Web of Science ®Google Scholar
• MAWER EB, HAYES ME, STILL PE et al.: Evidence for non-renal synthesis of 1,25-dihydroxyvitamin Din patients with inflammatory arthritis. Bone Miner. Res. (1991) 6(7):733–739.
   PubMedGoogle Scholar
• TETLOW LC, WOOLLEY DE: Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthr. Carta. (2001) 9(5):423–431.
   PubMed Web of Science ®Google Scholar
• ITO A, NOSE T, TAKAHASHI S, MORI Y: Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Lett. (1995) 360(1):75–79.
   PubMedGoogle Scholar
• TAKAHASHI S, INOUE T, HIGAKI M et al.: Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflamm. Res. (1997) 46(8):320–323.
   PubMedGoogle Scholar
• OWEN JL, IRAGAVARAPU-CHARYULU V, GUNJA-SMITH Z et al.: Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. Immunol (2003) 171(8):4340–4351.
   Google Scholar
• CALLEJAS NA, CASADO M, DIAZ-GUERRA MJ et al.: Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology (2001) 33(4):860–867.
   PubMedGoogle Scholar
• MURONO S, INOUE H, TANABE T et al.: Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Nati Acad. Sci. USA (2001) 98(12):6905–6910.
   PubMedGoogle Scholar
• YAO M, KARGMAN S, LAM EC et al.: Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. (2003) 63(3):586–592.
   PubMed Web of Science ®Google Scholar
• CIPOLLONE F, FAZIA M, IEZZI A et al.: Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation (2003) 107(11):1479–1485.
   PubMedGoogle Scholar
• LUAN Z, CHASE AJ, NEWBY AC: Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arteriosclec Thromb. Vasc. Biol. (2003) 23(5):769–775.
   PubMed Web of Science ®Google Scholar
• KOSSAKOWSKA AE, HINEK A, EDWARDS DR et al.: Proteolytic activity of human non-Hodgkin's lymphomas. Am. Pathol. (1998) 152(2):565–576.
   PubMedGoogle Scholar
• VACCA A, RIBATTI D, RIA R et al: Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev. Immunol. (2000) 7(2-4):77–88.
   Google Scholar
• LALANCETTE M, AOUDJIT F, POTWOROWSKI EF et al.: Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood (2000) 95(1):314–319.
   PubMedGoogle Scholar
• REIK W, MURRELL A: Genomic imprinting. Silence across the border. Nature (2000) 405(6785):408–409.
   Google Scholar
• HERMAN JG, BAYLIN SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl. Med. (2003) 349(21):2042–2054.
   PubMed Web of Science ®Google Scholar
• ROBERTSON KD, JONES PA: DNA methylation: past, present and future directions. Carcinogenesis (2000) 21(3)461–467.
   Google Scholar
• ROUNTREE MR, BACHMAN KE, HERMAN JG et al.: DNA methylation, chromatin inheritance, and cancer. Oncogene (2001) 20(24):3156–3165.
   PubMed Web of Science ®Google Scholar
• BAYLIN SB, ESTELLER M, ROUNTREE MR et al.: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. (2001) 10(7)687–692.
   Google Scholar
• VERMAAK D, AHMAD K, HENIKOFF S: Maintenance of chromatin states: an open-and-shut case. Carr: Opin. Cell Biol. (2003) 15(3):266–274.
   PubMedGoogle Scholar
• JONES PA: Cancer, death and methylation. Nature (2001) 409(6817):141,143-144.
   Google Scholar
• CHICOINE E, ESTEVE PO, ROBLEDO O et al.: Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem. Biophys. Res. Commun. (2002) 297(4):765–772.
   PubMed Web of Science ®Google Scholar
• •One of the first reports to provide direct evidence that MMP-9 steady state levels are controlled by DNA methylation at the level of its promoter.
   Google Scholar
• SATO N, MAEHARA N, SU GH et al.: Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness.' Natl. Cancer Inst. (2003) 95(4):327–333.
   Google Scholar
• •One of the first reports to provide direct evidence that MMP-9 steady state levels are controlled by DNA methylation at the level of its promoter.
   Google Scholar
• LEONE G, VOSO MT, TEOFILI L et al: Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clin. Immunol (2003) 109(1):89–102.
   PubMedGoogle Scholar
• ISSA JP, GARCIA-MANERO G, GILES FJ et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2004) 103(5):1635–1640.
   PubMed Web of Science ®Google Scholar
• HENNESSY BT, GARCIA-MANERO G, KANTARJIAN HM et al.: DNA methylation in haematological malignancies: the role of decitabine. Expert Opin. Investig. Drugs (2003) 12(12):1985–1993.
   PubMed Web of Science ®Google Scholar
• DENNY WA: Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). Biomed. Biotechnol (2003) 2003(1):48–70.
   PubMedGoogle Scholar
• MORELLI C, CAMPIONI K, PAROLIN C et al.: Activity of the matrix metalloproteinase-9 promoter in human normal and tumor cells. .1 Cell Physiol (2004) 199(1):126–133.
   Google Scholar
• AOUDJIT F, POTWOROWSKI EF, ST-PIERRE Y: Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. Immunol (1998) 160(6):2967–2973.
   Google Scholar
• AOUDJIT F, MASURE S, OPDENAKKER G et al.: Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int. Cancer (1999) 82(5):743–747.
   PubMedGoogle Scholar
• ••This study remains one of the strongest arguments supporting the hypothesis that MMP-9 confers a metastatic phenotype to a non-metastatic cell.
   Google Scholar
• BERNHARD EJ, GRUBER SB, MUSCHEL RJ: Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sri. USA (1994) 91(10):4293–4297.
   PubMed Web of Science ®Google Scholar
• COUSSENS LM, TINKLE CL, HANAHAN D et al.: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 103(3):481–490.
   PubMed Web of Science ®Google Scholar
• TCHETVERIKOV I, RONDAY HK, VAN EL B et al: MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann. Rheum. Dis. (2004) 63(7):881–883.
   PubMedGoogle Scholar
• •The study compares the level of expression of several members of the MIVIP family in synovial fluids of patients with arthritis.
   Google Scholar
• NELIMARKKA LO, NIKKARI ST, RAVANTI LS et al: Agenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor-a induced morphological change of human endothelial cells M vitro. Matrix Biol. (1998) 17(4):293–304.
   PubMedGoogle Scholar
• WATARI M, WATARI H, DISANTO ME et al.: Pro-inflammatory cytokines induce expression of matrix-metabolizing enzymes in human cervical smooth muscle cells. Am. Pathol. (1999) 154(6):1755–1762.
   PubMed Web of Science ®Google Scholar
• SAKAI T, KAMBE F, MITSUYAMA H et al.: Tumor necrosis factor a induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-icB: abrogation of the tumor necrosis factor a effect by proteasome inhibitors. J. Bone Miner. Res. (2001) a16(7):1272–1280.
   Google Scholar
• BHAGAVATHULA N, NERUSU KC, LAL A et al.: Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. Invest. Dermatol (2004) 122(1):130–139.
   PubMed Web of Science ®Google Scholar
• HETZEL M, WALCHER D, GRUB M et al.: Inhibition of MMP-9 expression by PPAR-y activators in human bronchial epithelial cells. Thorax (2003) 58(9):778–783.
   PubMedGoogle Scholar
• KINTSCHER U, GOETZE S, WAKINO S et al: Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1 -directed migration of monocytes. Ear: Pharmacol (2000) 401(3):259–270.
   PubMedGoogle Scholar
• CHANDRASEKAR N, MOHANAM S, LAKKA SS et al: Glial cell-induced endothelial morphogenesis is inhibited by interfering with extracellular signal-regulated kinase signaling. Gin. Cancer Res. (2003) 9(6):2342–2349.
   Google Scholar
• GE X, FU YM, MEADOWS GG: U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett. (2002) 179(2):133–140.
   PubMed Web of Science ®Google Scholar
• YAO J, XIONG S, KLOS K et al.: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-131 in human breast cancer cells. Oncogene (2001) 20(56):8066–8074.
   PubMedGoogle Scholar
• ESPARZA J, VILARDELL C, CALVO J et al.: Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways. Blood (1999) 94(8):2754–2766.
   Google Scholar
• PARK MJ, PARK IC, HURJH et al: Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by 5B203580, a specific inhibitor of p38-mitogen-activated protein kinase. Neurosurg. (2002) 97(1):112–118. Ha SIMON C, GOEPFERT H, BOYD D: Inhibition of the p38-mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 Type IV collagenase secretion and M vitro invasion. Cancer Res. (1998) 58(6):1135–1139.
   Google Scholar
• HUSSAIN S, ASSENDERJW, BOND M et al.: Activation of protein kinase C- is essential for cytokine-induced metalloproteinase- 1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J. Biol. Chem. (2002) 277(30):27345–27352.
   PubMedGoogle Scholar
• CHINTALA SK, SAWAYA R, AGGARWAL BB et al: Induction of matrix metalloproteinase-9 requires a polymerized actin cytoskeleton in human malignant glioma cells. J. Biol. Chem. (1998) 273(22):13545–13551.
   PubMedGoogle Scholar
• TROUSSARD AA, COSTELLO P, YOGANATHAN TN et al: The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (IVIMP-9). Oncogene (2000) 19(48):5444–5452.
   PubMedGoogle Scholar
• THANT AA, NAWA A, KIKKAWA F et al.: Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Mt pathways in ovarian cancer cells. Gin. Exp. Metastasis (2000) 18(5):423–428.
   PubMedGoogle Scholar
• MAJKA M, JANOWSKA-WIECZOREK A, RATAJCZAK J et al: Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood (2000) 96(13):4142–4151.
   PubMedGoogle Scholar
• PANEK RL, LU GH, KLUTCHKO SR et al.: hi vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Pharmacol Exp. The]: (1997) 283(3):1433–1444.
   PubMedGoogle Scholar
• YAO M, LAM EC, KELLY CR et al: Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer (2004) 90(3):712–719.
   PubMed Web of Science ®Google Scholar
• ATTIGA FA, FERNANDEZ PM, VVEERARATNA AT et al.: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. (2000) 60(16):4629–4637.
   PubMed Web of Science ®Google Scholar
• IISHI H, TATSUTA M, BABA M et al: Suppression by nimesulide of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin. Exp. Metastasis (2003) 20(6):555–560.
   PubMedGoogle Scholar
• ITO H, GARDNER-THORPE J, ZINNER MJ et al: Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery (2003) 134(2):221–226.
   PubMedGoogle Scholar
• KOHYAMA T, LIU X, ZHU YK et al.: Phosphodiesterase 4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by tumor necrosis factor-a and neutrophil elastase. Am. J. Respir. Cell. Ma Biol. (2002) 27(4):487–494.
   PubMedGoogle Scholar
• OKAMOTO T, VALACCHI G, GOHIL K et al.: 5-nitrosothiols inhibit cytokine-mediated induction of matrix metalloproteinase-9 in airway epithelial cells. Am. I Respir. Cell. Ma Biol. (2002) 27(4):463–473.
   PubMedGoogle Scholar
• GRIP O, JANCIAUSKIENE S, LINDGREN S: Atorvastatin activates PPAR-y and attenuates the inflammatory response in human monocytes. Liflamm. Res. (2002) 51(2):58–62.
   PubMed Web of Science ®Google Scholar
• DENOYELLE C, VASSE M, KORNER M et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis (2001) 22(8):1139–1148.
   PubMed Web of Science ®Google Scholar
• GANNE F, VASSE M, BEAUDEUXJL et al.: Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes - a possible protective mechanism against atherothrombosis. Thromb. Haemost. (2000) 84(4):680–688.
   PubMedGoogle Scholar
• MAYO MW, DENLINGER CE, BROAD RIVI et al: Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-icB through the Akt pathway. Biol. Chem. (2003) 278(21):18980–18989.
   Google Scholar
• CHINTALA SK, KYRITSIS AP, MOHAN PM et al: Altered actin cytoskeleton and inhibition of matrix metalloproteinase expression by vanadate and phenylarsine oxide, inhibitors of phosphotyrosine phosphatases: modulation of migration and invasion of human malignant glioma cells. Carcinog. (1999) 26(4):274–285.
   Google Scholar
• WU Y, PALAD AJ, WASILENKO WJ et al.: Inhibition of head and neck squamous cell carcinoma growth and invasion by the calcium influx inhibitor carboxyamido-triazole. Clin. Cancer Res. (1997) 3(11):1915–1921.
   PubMedGoogle Scholar
• BELL OSTA S, VIA D, CANAVESI M et al.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. (1998) 18(11):1671–1678.
   PubMedGoogle Scholar
• CIPOLLONE F, FAZIA M, IEZZI A et al: Blockade of the angiotensin II Type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation (2004) 109(12):1482–1488.
   PubMedGoogle Scholar
• YANAMANDRA N, GUMIDYALA KV, WALDRON KG et al: Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis. Oncogene (2004) 23(12):2224–2230.
   PubMedGoogle Scholar
• •Using an antisense cathepsin B cDNA expression plasmid, the authors report that cathepsin B inhibits IVEVIP-9, but not IVEVIP-2, expression via either ERK or PI3K, thereby reducing their invasive behaviour.
   Google Scholar
• INOUE K, SLATON JW, EVE BY et al: Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Gin. Cancer Res. (2000) 6(5):2104–2119.
   Google Scholar
• HIRATSUKA S, NAKAMURA K, IWAI S et al.: MMP-9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell (2002) 2(4):289–300.
   PubMed Web of Science ®Google Scholar
• LAKKA SS, JASTI SL, GONDI C et al: Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene (2002) 21(36):5601–5608.
   PubMed Web of Science ®Google Scholar
• IZAWA JI, SWEENEY P, PERROTTE P et al.: Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-P gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Gin. Cancer Res. (2002) 8(4):1258–1270.
   Google Scholar
• HAUCK CR, SIEG DJ, HSIA DA et al: Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res. (2001) 61(19):7079–7090.
   PubMed Web of Science ®Google Scholar
• HUANG SM, LI J, HARARI PM: Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Ma Cancer Tiler. (2002) 1(7):507–514.
   PubMed Web of Science ®Google Scholar
• PRICE NM, GILMAN RH, UDDIN J et al.: Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-a-dependent monocyte networks. Immunol. (2003) 171(10):5579–5586.
   Google Scholar
• ROBINSON SC, SCOTT KA, BALKWILL FR: Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-a. Eur. Immunol. (2002) 32(2):404–412.
   PubMed Web of Science ®Google Scholar
• ISMAIR MG, RIES C, LOTTSPEICH F et al.: Autocrine regulation of MMP-9 gene expression and secretion by tumor necrosis factor-a (TNF-a) in NB4 leukemic cells: specific involvement of TNF receptor Type 1. Leukemia (1998) 12(7):1136–1143.
   PubMedGoogle Scholar
• SWEENEY P, KARASHIMA T, KIM SJ et al.: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase Type 9 production. Clin. Cancer Res. (2002) 8(8):2714–2724.
   PubMedGoogle Scholar
• DAS A, FANSLOW W, CERRETTI D et al.: Angiopoietin/Tek interactions regulate mmp-9 expression and retinal neovascularization. Lab. Invest. (2003) 83(11):1637–1645.
   PubMed Web of Science ®Google Scholar
• RUHUL AMIN AR, SENGA T, OO ML et al.: Secretion of matrix metalloproteinase-9 by the proinflammatory cytokine, a role for the dual signalling pathways, Akt and Erk. Genes Cells (2003) 8(6):515–523.
   PubMedGoogle Scholar
• TANAKA S, SUGIMACHI K, YAMASHITA YI Y et al.: Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology (2002) 35(4):861–867.
   Google Scholar
• LIU E, THANT AA, KIKKAWA F et al: The Ras-mitogen-activated protein kinase pathway is critical for the activation of matrix metalloproteinase secretion and the invasiveness in v-crk-transformed 3Y1. Cancer Res. (2000) 60(9):2361–2364.
   PubMedGoogle Scholar
• REDDY KB, KRUEGER JS, KONDAPAKA SB et al.: Mitogen-activated protein kinase (MAPK) regulates the expression of progelatinase B (MMP-9) in breast epithelial cells. Int.j Cancer (1999) 82(2):268–273.
   PubMed Web of Science ®Google Scholar
• ARAI K, LEE SR, LO EH: Essential role for ERK mitogen-activated protein kinase in matrix metalloproteinase-9 regulation in rat cortical astrocytes. GYM (2003) 43(3):254–264.
   Google Scholar
• AHMED N, PANSINO F, BAKER M et al.: Association between avI36 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.' Cell Biochem. (2002) 84(4):675–686.
   Google Scholar
• WORLEY JR, BAUGH MD, HUGHES DA et al.: Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of perwdsome proliferator-activated receptor-y (PPAR y) agonists and 9-cis-retinoic acid. Biol. Chem. (2003) 278(51):51340–51346.
   Google Scholar
• HASHIMOTO K, ETHRIDGE RT, EVERS BM: Perwdsome proliferator-activated receptor y ligand inhibits cell growth and invasion of human pancreatic cancer cells. hat. Gastrointest. Cancer (2002) 32(1):7–22.
   Google Scholar
• MARX N, SCHONBECK U, LAZAR MA et al.: Perwdsome proliferator-activated receptor y activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. (1998) 83(11):1097–1103.
   PubMedGoogle Scholar
• MARX N, SUKHOVA G, MURPHY C et al.: Macrophages in human atheroma contain PPARy differentiation-dependent perwdsomal proliferator-activated receptor y (PPARy) expression and reduction of MMP-9 activity through PPARy activation in mononuclear phagocytes in vitro. Am. Pathol (1998) 153(1):17–23.
   PubMed Web of Science ®Google Scholar
• VAYALIL PK, KATIYAR SK: Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and -9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-icB in human prostate carcinoma DU-145 cells. Prostate (2004) 59(1):33–42.
   PubMedGoogle Scholar
• MAEDA-YAMAMOTO M, SUZUKI N, SAWAI Y et al.: Association of suppression of extracellular signal-regulated kinase phosphorylation by epigallocatechin gallate with the reduction of matrix metalloproteinase activities in human fibrosarcoma HT1080 cells. .1 Agric. Food Chem. (2003) 51(7):1858–1863.
   Google Scholar
• LIU JD, CHEN SH, LIN CL et al: Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. Cell Biochem. (2001) 83(4):631–642.
   PubMedGoogle Scholar
• KANG JL, LEE HW, LEE HS et al: Time course for inhibition of lipopolysaccharide-induced lung injury by genistein: relationship to alteration in nuclear factor-KB activity and inflammatory agents. Crit. Care Med. (2003) 31(2):517–524.
   PubMedGoogle Scholar
• ALHASAN SA, ARANHA O, SARKAR FH: Genistein elicits pleiotropic molecular effects on head and neck cancer cells. Clin. Cancer Res. (2001) 7(12):4174–4181.
   PubMed Web of Science ®Google Scholar
• TAKAFUJI S, ISHIDA A, MIYAKUNI Y et al.: Matrix metalloproteinase-9 release from human leukocytes.' Investig. Allergol Clin. Immunol (2003) 13(1):50–55.
   Google Scholar
• FUTAMURA M, KAMIYA S, TSUKAMOTO M et al.: Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene (2001) 20(46):6724–6730.
   PubMedGoogle Scholar
• LOHI J, KESKI-OJA J: Calcium ionophores decrease pericellular gelatinolytic activity via inhibition of 92-kDa gelatinase expression and decrease of 72-kDa gelatinase activation. Biol. Chem. (1995) 270(29):17602–17609.
   Google Scholar
• ZHANG Y, DEWITT DL, MCNEELY TB et al.: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. Clin. Invest. (1997) 99(5):894–900.
   Google Scholar
• MOON SK, KIM HM, KIM CH: PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-icB and AP-1 in vascular smooth muscle cells. Arch. Biochem. Biophys. (2004) 421(2):267–276.
   PubMedGoogle Scholar
• PARK MJ, KIM MS, PARK IC et al: PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation. Cancer Res. (2002) 62(21):6318–6322.
   PubMedGoogle Scholar
• TAMATANI T, AZUMA M, ASHIDA Y et al.: Enhanced radiosensitization and chemosensitization in NE-KB-suppressed human oral cancer cells via the inhibition of 7-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int. I Cancer (2004) 108(6):912–921.
   PubMed Web of Science ®Google Scholar
• HUANG S, PETTA WAY CA, UEHARA H et al.: Blockade of NF-icB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 20(31):4188–4197.
   PubMedGoogle Scholar
• BOND M, CHASE AJ, BAKER AH et al: Inhibition of transcription factor NF-icB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. (2001) 50(3):556–565.
   PubMedGoogle Scholar
• MOON SK, CHO GO, JUNG SY et al: Quercetin exerts multiple inhibitory effects on vascular smooth muscle cells: role of ERK1/2, cell-cycle regulation, and matrix metalloproteinase-9. Biochem. Biophys. Res. Commun. (2003) 301(4):1069–1078.
   PubMedGoogle Scholar
• STUHLMEIER KM: Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. I Rheumatol (2003) 30(11):2330–2337.
   Google Scholar
• ZEIGLER ME, CHI Y, SCHMIDT T et al.: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. I Cell Physiol (1999) 180 (2):271–284.
   PubMedGoogle Scholar
• NAKAMURA Y, ESNAULT S, MAEDA T et al.: Ets-1 regulates TNF-a-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts. Immunol. (2004) 172(3):1945–1952.
   Google Scholar
• •The authors showed that human fibroblasts expressing oligonudeotides specific against Ets partially inhibit the expression of the proform of MMP-9 induced by TNF-a. The data emphasise the importance of Ets in the control of IVEVIP-9 in inflammatory pulmonary conditions.
   Google Scholar
• SATO H, KITA M, SEIKI M: v-Src activates the expression of 92-kDa Type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. Biol. Chem. (1993) 268(31):23460–23468.
   Google Scholar
• YE S: Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.Matrix Biol. (2000) 19(7):623–629.
   PubMedGoogle Scholar